At the conclusion of this course, learners should be able to:

1. Discuss the changes in thyroid pathology related to the latest WHO classification. 

2. Describe the diagnostic criteria for the new entity of differentiated high grade thyroid carcinoma.

3. Discuss the basis for grading medullary thyroid carcinomas.

4. List the gene mutations and fusions categorized as BRAF-like and RAS-like alterations in thyroid neoplasia.

5. Contrast BRAF-like and RAS-like thyroid tumors in terms of their morphologic features and clinical behavior.

Accreditation

The American Thyroid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American Thyroid Association designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American Thyroid Association ensures that anyone in a position to control the content of the educational activity (planners/speakers/authors/discussants/moderators) disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”) held in the last 24 months.

The ACCME also requires that ATA manage any reported relevant financial relationships and eliminate the potential for bias during the educational activity. Any relevant financial relationships noted have been mitigated. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

None of the faculty have anything to disclose.